Charles E Hay

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2472466/publications.pdf

Version: 2024-02-01

37 papers	3,140 citations	394421 19 h-index	377865 34 g-index
38 all docs	38 docs citations	38 times ranked	1803 citing authors

#	Article	IF	Citations
1	Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood, 2007, 109, 1870-1877.	1.4	646
2	Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood, 2007, 110, 815-825.	1.4	461
3	The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood, 2012, 119, 1335-1344.	1.4	391
4	The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. British Journal of Haematology, 2006, 133, 591-605.	2.5	305
5	The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977â€“99. Journal of Thrombosis and Haemostasis, 2004, 2, 1047-1054.	3.8	247
6	Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood, 2013, 122, 1954-1962.	1.4	188
7	Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood, 2011, 117, 6367-6370.	1.4	173
8	Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood, 2014, 124, 3389-3397.	1.4	110
9	Clinical evaluation of moroctocog alfa (AFâ€CC), a new generation of Bâ€domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to fullâ€length recombinant factor VIII. Haemophilia, 2009, 15, 869-880.	2.1	89
10	Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia, 2018, 24, 344-347.	2.1	73
11	European retrospective study of realâ€life haemophilia treatment. Haemophilia, 2017, 23, 105-114.	2.1	61
12	Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. Haemophilia, 2019, 25, 205-212.	2.1	51
13	The incidence of factor <scp>VIII</scp> inhibitors in severe haemophilia A following a major switch from fullâ€length to Bâ€domainâ€deleted factor <scp>VIII</scp>: a prospective cohort comparison. Haemophilia, 2015, 21, 219-226.	2.1	41
14	Mortality in congenital hemophilia AÂâ€“Âa systematic literature review. Journal of Thrombosis and Haemostasis, 2021, 19, 6-20.	3.8	41
15	Novel, human cell lineâ€derived recombinant factor VIII (humanâ€cl rhFVIII; Nuwiq^{Â®}) in adults with severe haemophilia A: efficacy and safety. Haemophilia, 2016, 22, 225-231.	2.1	34
16	Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia, 2013, 19, 660-667.	2.1	30
17	Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies. Haemophilia, 2019, 25, 398-407.	2.1	27
18	Firstâ€line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties. Haemophilia, 2017, 23, 654-659.	2.1	25

#	Article	IF	Citations
19	The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors Organisation. Haemophilia, 2017, 23, 728-735.	2.1	20
20	Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. Haemophilia, 2021, 27, 932-937.	2.1	16
21	Evaluation of the use of global haemostasis assays to monitor treatment in factor <scp>XI</scp> deficiency. Haemophilia, 2017, 23, 273-283.	2.1	14
22	Pharmacokinetics, safety and efficacy of a recombinant factor <scp>IX</scp> product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia, 2018, 24, 104-112.	2.1	14
23	Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. Journal of Thrombosis and Haemostasis, 2021, 19, 32-41.	3.8	14
24	Evaluation of the use of rotational thromboelastometry in the assessment of FXI deficency. Haemophilia, 2017, 23, 449-457.	2.1	11
25	The immunogenicity of ReFacto <scp>AF</scp> (moroctocog alfa <scp>AF</scp>â€<scp>CC</scp>) in previously untreated patients with haemophilia A in the United Kingdom. Haemophilia, 2018, 24, 896-901.	2.1	11
26	In vitro comparison of the effect of two factor XI (FXI) concentrates on thrombin generation in major <scp>FXI</scp> deficiency. Haemophilia, 2016, 22, 403-410.	2.1	10
27	The bleeding phenotype in people with nonsevere hemophilia. Blood Advances, 2022, 6, 4256-4265.	5.2	10
28	Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. Journal of Thrombosis and Haemostasis, 2021, 19, 21-31.	3.8	7
29	Efficacy and safety of Nuwiq^{Â®} (humanâ€el rh<scp>FVIII</scp>) in patients with severe haemophilia A undergoing surgical procedures. Haemophilia, 2018, 24, 70-76.	2.1	6
30	Use of the <scp>UKHCDO</scp> Database for a postmarketing surveillance study of different doses of recombinant factor <scp>VII</scp>a in haemophilia. Haemophilia, 2017, 23, 376-382.	2.1	4
31	Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. Haemophilia, 2020, 26, 966-974.	2.1	4
32	Weekly recombinant <scp>FIX</scp> prophylaxis for severe haemophilia B in normal clinical practice: data from <scp>UKHCDO</scp> and Finland. Haemophilia, 2017, 23, e240-e243.	2.1	3
33	Expecting the unexpected: Acquired haemophilia A in a patient with homozygous factor V deficiency. Haemophilia, 2019, 25, e101-e103.	2.1	1
34	Switching factor products: selecting patients and managing the process. The Journal of Haemophilia Practice, 2013, 1, 24-29.	0.4	1
35	Editorial Foreword. Haemophilia, 1997, 3, 1-1.	2.1	0
36	Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.. Blood, 2018, 132, 1184-1184.	1.4	0

#	Article	IF	Citations
37	Management of multiple myeloma in a patient with haemophilia with concurrent emicizumab â€“ case report. The Journal of Haemophilia Practice, 2021, 8, 136-140.	0.4	0